4th Quarter - Report

GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

Firm
Client
Income
—
Expenses
$960,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Issues related to healthcare funding and cost-savings.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); State, Dept of (DOS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Foreign Relations FOR

Issues related to access to pharmaceuticals, international finance for health services and intellectual property protection.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —

Contacted: SENATE; State, Dept of (DOS); Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Copyright/Patent/Trademark CPT

HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to access to pharmaceuticals and intellectual property protection. Intellectual property reform. S.1137 - PATENT Act & HR. 9 - Innovation Act.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB); Commerce, Dept of (DOC); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); U.S. Trade Representative (USTR)

Bills named: H.R. 9 (114th), S. 1137 (114th)

Health Issues HCR

Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.The FOCUS program.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: State, Dept of (DOS); Health & Human Services, Dept of (HHS); SENATE; Veterans Affairs, Dept of (VA); Commerce, Dept of (DOC); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 6 (114th), S. 1287 (114th), S. 3056 (114th), S. 524 (114th)

Medicare/Medicaid MMM

Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; Implementation of Public Law No: 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: U.S. Trade Representative (USTR); State, Dept of (DOS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; Veterans Affairs, Dept of (VA); Commerce, Dept of (DOC)

Bills named: H.R. 6 (114th)

Trade (domestic/foreign) TRD

International trade and protection of intellectual property

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Veterans Affairs, Dept of (VA); U.S. Trade Representative (USTR); SENATE; Commerce, Dept of (DOC); State, Dept of (DOS); HOUSE OF REPRESENTATIVES

Law Enforcement/Crime/Criminal Justice LAW

Incarcerated population relating to Hepatitis C and health care.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: SENATE; Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC)

Pharmacy PHA

Coverage of pharmaceuticals, cost-sharing and other access issues; H.R. 6 - 21st Century Cures Act; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and Affordable Care Act implementation; FDA issues and 340B. S. 3056 - CREATES Act of 2016.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: Commerce, Dept of (DOC); SENATE; Veterans Affairs, Dept of (VA); State, Dept of (DOS); U.S. Trade Representative (USTR); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 3056 (114th), H.R. 6 (114th)

Veterans VET

Appropriations; Education related to Hepatitis C treatment guidelines (veterans) and funding issues (FY17 Appropriations bill). Issues related to coverage, access and reimbursement of pharmaceuticals for veterans. Education related to Implementation of Veterans Access to Care Act, HR 4810/3230 and PL 113-146. Health care for judiciary involved veterans.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); State, Dept of (DOS); U.S. Trade Representative (USTR)

Bills named: H.R. 4810 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.